5月23日，荣昌生物今日收盘57.83元，上涨2.08%，最新市净率17.78，创256天以来新低，总市值314.95亿元。
股东方面，截至2025年3月31日，荣昌生物股东户数6742户，较上次增加49户，户均持股市值35.28万元，户均持股数量2.76万股。
荣昌生物制药(烟台)股份有限公司的主营业务是开发与商业化创新、有特色的同类首创（first-in-class）与同类最佳（best-in-class）生物药，以创造药物临床价值为导向，为自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域提供安全、有效、可及的临床解决方案，以满足大量尚未被满足的临床需求。公司的主要产品是泰它西普（RC18）、维迪西妥单抗（RC48）、RC28、RC88、RC148、RC278。
最新一期业绩显示，2025年一季报，公司实现营业收入5.26亿元，同比59.17%；净利润-254144470.06元，同比27.16%，销售毛利率83.26%。
| 序号 | 股票简称 | PE(TTM) | PE(静) | 市净率 | 总市值(元) |
| 21 | 荣昌生物 | -22.93 | -21.45 | 17.78 | 314.95亿 |
| 行业平均 | 59.47 | 47.60 | 9.76 | 192.73亿 | |
| 行业中值 | 40.78 | 36.78 | 2.84 | 77.48亿 | |
| 1 | 优宁维 | -2023.58 | 251.66 | 1.24 | 25.54亿 |
| 2 | 万泰生物 | -1192.46 | 810.98 | 7.06 | 861.55亿 |
| 3 | 仁度生物 | -148.57 | -195.80 | 1.67 | 15.30亿 |
| 4 | 诺诚健华 | -141.19 | -89.80 | 5.86 | 395.70亿 |
| 5 | 百济神州 | -112.29 | -71.38 | 14.10 | 3553.66亿 |
| 6 | 诺思兰德 | -110.93 | -99.80 | 13.94 | 45.09亿 |
| 7 | 通化东宝 | -102.00 | -353.91 | 2.33 | 151.20亿 |
| 8 | 双鹭药业 | -70.91 | -94.04 | 1.24 | 69.65亿 |
| 9 | 康希诺 | -64.58 | -37.55 | 2.90 | 142.28亿 |
| 10 | 益方生物 | -63.62 | -56.82 | 7.71 | 136.49亿 |
| 11 | 百利天恒 | -58.91 | 29.06 | 31.96 | 1077.45亿 |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.